Format

Send to

Choose Destination
Ir J Med Sci. 2012 Jun;181(2):211-4. doi: 10.1007/s11845-011-0780-7. Epub 2011 Nov 3.

A single institution experience of streptozocin/fluorouracil combination chemotherapy: a case series.

Author information

1
Trinity College Dublin, St. James's Hospital, James's Street, Dublin 2, Ireland. jarushka_14@yahoo.com

Abstract

BACKGROUND:

The combination chemotherapy regimen of streptozocin and 5-fluorouracil (FU/STZ) has been used for the treatment of metastatic neuroendocrine tumours.

AIM:

The aim of this study was to analyse the use of this regimen in a tertiary oncology referral centre over a 10-year period.

METHOD:

We retrospectively analysed nine cases from February 2000 to May 2010. Patient demographics, chemotherapy schedule, toxicities, progression-free and overall survival were tabulated for each patient.

RESULT:

The median progression-free survival was 17 months (range 3-48+ months), and overall survival 31 months (range 12-53+ months) with no toxicity related deaths.

CONCLUSION:

FU/STZ was a well-tolerated regimen that produced significant benefit in the setting of metastatic and progressive disease. Our case series demonstrated comparable progression-free survival and overall survival in relation to randomized controlled studies and previous case series.

PMID:
22048868
DOI:
10.1007/s11845-011-0780-7
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center